4.7 Article

The Prevalence of GNAS Deficiency-Related Diseases in a Large Cohort of Patients Characterized by the EuroPHP Network

Journal

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 101, Issue 10, Pages 3657-3668

Publisher

ENDOCRINE SOC
DOI: 10.1210/jc.2015-4310

Keywords

-

Funding

  1. European Network
  2. European Society for Pediatric Endocrinology Research Unit
  3. Paris-Sud University (projet Attractivite)
  4. French National Research Agency
  5. Italian Ministry of Health Grant [GR-2009-1608394]
  6. Ricerca Corrente Funds
  7. French Society of Pediatric Endocrinology and Diabetology
  8. Instituto de Salud Carlos III (Institute of Health Carlos III) of Ministry of Economy and Competitiveness
  9. European Regional Development Fund Grant [PI13/00467]
  10. Basque Department of Health Grant [GV2014111017]
  11. INSERM [U1169]
  12. I3SNS Program of the Spanish Ministry of Health Grant [CP03/0064 SIVI 1395/09]
  13. University of Basque Country Grant [48198]

Ask authors/readers for more resources

Context: The term pseudohypoparathyroidism (PHP) was coined to describe the clinical condition resulting from end-organ resistance to parathormone (rPTH), caused by genetic and/or epigenetic alterations within or upstream of GNAS. Although knowledge about PHP is growing, there are few data on the prevalence of underlying molecular defects. Objective: The purpose of our study was to ascertain the relative prevalence of PHP-associated molecular defects. Design: With a specially designed questionnaire, we collected data from all patients (n = 407) clinically and molecularly characterized to date by expert referral centers in France, Italy, and Spain. Results: Isolated rPTH (126/407, 31%) was caused only by epigenetic defects, 70% of patients showing loss of imprinting affecting all four GNAS differentially methylated regions and 30% loss of methylation restricted to the GNAS A/B: TSS-DMR. Multihormone resistance with no Albright's hereditary osteodystrophy (AHO) signs (61/407, 15%) was essentially due to epigenetic defects, although 10% of patients had point mutations. In patients with rPTH and AHO (40/407, 10%), the rate of point mutations was higher (28%) and methylation defects lower (about 70%). In patients with multihormone resistance and AHO (155/407, 38%), all types of molecular defects appeared with different frequencies. Finally, isolated AHO (18/407,4%) and progressive osseous heteroplasia (7/407, 2%) were exclusively caused by point mutations. Conclusion: With European data, we have established the prevalence of various genetic and epigenetic lesions in PHP-affected patients. Using these findings, we will develop objective criteria to guide cost-effective strategies for genetic testing and explore the implications for management and prognosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available